Literature DB >> 2548769

Regulation of cardiac beta-adrenergic receptors by captopril. Implications for congestive heart failure.

A S Maisel1, C Phillips, M C Michel, M G Ziegler, S M Carter.   

Abstract

The interaction of the renin-angiotensin system and the sympathetic nervous system in patients with congestive heart failure is not well understood. We tested the hypothesis that angiotensin-converting enzyme inhibitors can resensitize the beta-adrenergic receptor system. Guinea pigs were given captopril, isoproterenol, or both for 2 weeks. At death, cardiac sarcolemmal and light vesicle fractions and intact mononuclear leukocytes were prepared. Captopril treatment led to an up-regulation of cardiac beta 1- but not mononuclear leukocyte beta 2-adrenergic receptors and an increase in isoproterenol-stimulated adenylate cyclase activity in the heart. Animals treated with isoproterenol developed cardiac hypertrophy, had increased plasma norepinephrine levels, and had a decreased number and responsiveness of both cardiac and mononuclear leukocyte beta-adrenergic receptors. Concomitant treatment with captopril attenuated alterations of heart weight, plasma norepinephrine levels, and cardiac beta-receptor density and function. In contrast to its cardiac effects, captopril treatment did not diminish the down-regulation of mononuclear leukocyte beta 2-adrenergic receptors by isoproterenol. Our data suggest that captopril may resensitize the cardiac but not the mononuclear leukocyte beta-adrenergic receptor-adenylate cyclase system after long-term catecholamine exposure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548769     DOI: 10.1161/01.cir.80.3.669

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Depression as a potential modulator of Beta-adrenergic-associated leukocyte mobilization in heart failure patients.

Authors:  Laura S Redwine; Petra H Wirtz; Suzi Hong; Jos A Bosch; Jos Bosch; Michael G Ziegler; Barry Greenberg; Paul J Mills
Journal:  J Am Coll Cardiol       Date:  2010-11-16       Impact factor: 24.094

2.  Diminished post-rest potentiation of contractile force in human dilated cardiomyopathy. Functional evidence for alterations in intracellular Ca2+ handling.

Authors:  B Pieske; M Sütterlin; S Schmidt-Schweda; K Minami; M Meyer; M Olschewski; C Holubarsch; H Just; G Hasenfuss
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Does treatment with beta-adrenoceptor antagonists in vivo alter human adenylate cyclase responsiveness in vitro?

Authors:  M C Michel; M Klüppel; T Philipp; O E Brodde
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

4.  Pharmacologic characterization in vitro and in vivo of iodine 123-labeled derivatives of the beta-adrenoceptor antagonist CGP12177, designed for the imaging of cardiac beta-receptors.

Authors:  E A Dubois; G A Somsen; J C van den Bos; A G Janssen; G J Boer; H D Batink; E A van Royen; M Pfaffendorf; P A van Zwieten
Journal:  J Nucl Cardiol       Date:  1996 May-Jun       Impact factor: 5.952

Review 5.  Inhibitors of the renin-angiotensin system in established cardiac failure.

Authors:  K Chatterjee
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

6.  G-protein-coupled receptor kinase activity is increased in hypertension.

Authors:  R Gros; J L Benovic; C M Tan; R D Feldman
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

7.  Regulation of beta-adrenoceptors in the guinea-pig sinoatrial node.

Authors:  F D Russell; A R Kompa; P Molenaar; R J Summers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-05       Impact factor: 3.000

8.  The ACE-inhibitor captopril improves myocardial perfusion in spontaneously diabetic (BB) rats.

Authors:  R Rösen; A F Rump; P Rösen
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

Review 9.  Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects.

Authors:  Oleg E Osadchii
Journal:  Heart Fail Rev       Date:  2007-03-27       Impact factor: 4.654

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.